Antibody neutralizing human respiratory syncytial virus
US11008380B2 · kind B2 · utility
0Cited by
28References
6Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 7, 2019 |
| Grant date | May 18, 2021 |
| Priority date | — |
| Expiry date | Jun 7, 2039 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to monoclonal antibodies which have high anti-RSV neutralizing titers. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. The invention yet further provides for diagnostic, prophylactic and therapeutic methods employing the antibodies and nucleic acids of the invention, particularly as a passive immunotherapy agent in infants and the elderly.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.